We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 159

SEC brings fraud case against biopharmaceutical company, three other companies and four executives for misleading investors about sole product and insider trading
  • Porter Wright Morris & Arthur LLP
  • USA
  • August 2 2011

On Monday, August 1, 2011, the SEC filed suit against eight defendants for making false statements in public filings regarding the status of the human clinical trials for the drug SF-1019 by Argyll Biotechnologies LLC.

MDL court rules toy manufacturer’s refund program superior to class certification
  • Shook Hardy & Bacon LLP
  • USA
  • October 14 2010

A federal court in Illinois has denied the motion for class certification filed by the lead plaintiffs in multidistrict litigation (MDL) seeking damages and injunctive relief against the manufacturer, distributor and three major retailers of a children's toy product that was recalled after it was found to be tainted with the "so-called date rape drug GHB."

Amendments to Illinois Vehicle Code address bus driver disqualification and school bus communication devices
  • Franczek Radelet PC
  • USA
  • August 31 2010

Governor Quinn recently signed into law Public Acts 96-0962, 96-1066 and 96-1182 which amend the Illinois Vehicle Code as it relates to school bus drivers and school buses.

Omnicare v. UnitedHealth Group: important considerations for companies exchanging information in a merger or acquisition context
  • Hogan Lovells
  • USA
  • February 4 2009

On January 16, 2009, a federal district court in Chicago granted summary judgment to the defendants in Omnicare, Inc. v. UnitedHealth Group, Inc., et al, No. 1:06-cv-06235, a lawsuit involving information exchanged between competitors engaged in merger discussions and due diligence.

Ovation Pharmaceutical, Inc
  • Reed Smith LLP
  • USA
  • January 7 2009

On Dec. 16, 2008, the FTC filed a complaint against Ovation Pharmaceuticals, Inc. in the U.S. District Court for the District of Minnesota, alleging that the Illinois-based drug manufacturer illegally charged monopoly prices for its drug that is used to treat a life-threatening heart condition in premature infants, after purchasing the only similar medicine from a competitor in 2006.

Illinois federal court: FDA premarket approval process preempts state law causes of action
  • Locke Lord LLP
  • USA
  • December 9 2008

Relying on the Supreme Court’s decision in Riegel, the U.S. District Court for the Northern District of Illinois recently held that the Food and Drug Administration’s (“FDA”) extensive premarket approval (“PMA”) process for Class III medical devices preempts state law causes of action for injuries allegedly caused by those devices.

John J. Richardson
  • Dinsmore & Shohl LLP